PhaseRx is a preclinical biopharmaceutical company dedicated to developing products for the treatment of inherited enzyme deficiencies in the liver using intracellular enzyme replacement therapy. The Company's i-ERT approach is enabled by its proprietary Hybrid mRNA TechnologyTM platform.